On July 24, 2025, Beijing GoBroad Hospital and AstraZeneca Global R&D China held a grand “Strategic Collaboration Signing and Plaque Unveiling Ceremony on Clinical Research in Cell Therapy” in Beijing. The two parties announced an in-depth collaboration focusing on cell therapy, joining forces to advance clinical research and translational application of this cutting-edge technology in China, accelerating the delivery of breakthrough therapeutic solutions to patients.

In her speech, Ms. He Jing, Senior Vice President of AstraZeneca Global and Head of Global R&D China, stated:
"Earlier this year, AstraZeneca announced the establishment of its sixth global strategic R&D center in Beijing, demonstrating our strong confidence in Beijing's world-class life science innovation ecosystem. We are delighted to form this strategic partnership with Beijing GoBroad Hospital. By leveraging our respective strengths in R&D innovation and clinical research, we will create strong synergies to accelerate the clinical translation and application of cutting-edge cell therapy technologies and drive China’s scientific innovation onto the global stage."

Mr. Zheng Xiaoyu, CEO of GoBroad Healthcare Group, expressed strong confidence in the prospects of the partnership in his welcoming remarks:
"As a public service platform for clinical research in Beijing, GoBroad Hospital brings together top clinical research experts and support teams, while actively integrating Beijing's rich scientific resources. This strategic collaboration with AstraZeneca will enable high-level clinical research in cell therapy and jointly build a hub of medical innovation, promoting high-quality development in the life and health industry."

The signing and plaque unveiling ceremony concluded successfully in the presence of senior executives from both sides and distinguished guests. Mr. Zheng Weiyi, Vice President of AstraZeneca Global R&D China and Head of Clinical Operations, subsequently shared insights on AstraZeneca's R&D pipeline and future strategies, highlighting the company's strong capabilities and forward-looking vision in innovative drug development. Mr. Shang Hua, Executive President of Beijing GoBroad Hospital, presented an overview of the hospital's disciplinary strengths and the unique value of its research-oriented model, emphasizing its core competitiveness as a platform for translational innovation.

In the subsequent salon discussion, participants engaged in lively exchanges on technology trends, R&D models, and collaboration mechanisms in cell therapy research, generating numerous insightful and constructive ideas.

Through this strategic partnership, the two sides will integrate R&D and clinical resources, focus on clinical research in cell therapy, and strive to accelerate the translation of scientific discoveries into clinical applications. Together, they aim to explore breakthrough therapies, address unmet medical needs, and inject strong momentum into innovation and upgrading of China's biopharmaceutical industry. Both parties look forward to delivering tangible outcomes from this collaboration in the near future.